Empowering Women’s Health: SheMed Secures €43 million to Revolutionize Personalized Healthcare in the UK

SheMed Raises €43 Million to Advance Personalized Healthcare for Women

SheMed, a female-founded HealthTech company based in London, has secured €43 million in funding to enhance its innovative health platform and drive new breakthroughs in preemptive healthcare. The funding will support the expansion of SheMed’s UK operations, including scaling its medical and technology teams, strengthening clinical infrastructure, and improving its data-driven capabilities.

“After more than a decade of searching for answers to an undiagnosed health issue,” said Olivia Ferro, Co-founder and CEO of SheMed, “I understand the transformative power of the right diagnosis and treatment. SheMed was created to provide women with the personalized support that I struggled to find: care that listens, understands, and empowers.”

The new funding for SheMed aligns with the increasing investment activity in UK and European HealthTech, particularly in preventative care and women’s health. Other companies in the UK, such as Numan and Hormona, have also received significant funding to expand their healthcare platforms.

SheMed’s latest funding signifies a growing investor interest in women’s health and metabolic-care platforms as key areas of growth in European healthcare innovation. The company’s services have seen high demand, with women seeking personalized and supportive healthcare solutions.

Founded in April 2024 by sisters Olivia and Chloe Ferro, SheMed has quickly become a market leader in addressing the gap in women’s healthcare. The company’s integrated platform offers medical oversight, wellness tracking, and round-the-clock support, redefining the healthcare space.

The new investment will enable SheMed to conduct research and initiatives to improve access to high-quality, personalized care for women across the UK. Known for its leading GLP-1 and weight-management platform, SheMed has already helped over 60,000 members achieve lasting health results.

SheMed is set to release the results of the first-ever female-focused GLP-1 clinical study, providing insights into how GLP-1 medications impact women’s hormonal and metabolic responses. This study marks a significant milestone in women’s metabolic-health research and will help refine future treatment pathways.